Orchestra BioMed Holdings, Inc. Financing Cash Flow
Orchestra BioMed Holdings, Inc. (OBIO) reported Financing Cash Flow of $40.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $34.75M.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.53M.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $12.66M, a 9.23% decline year-over-year.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $76.40M, a 408.13% increase year-over-year.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $88.33M, a 202.81% increase from fiscal 2024.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $29.17M, a 36.88% decline from fiscal 2023.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $46.22M, a 55.24% decline from fiscal 2022.
- Orchestra BioMed Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $103.26M.
| Period end | Net Cash Provided by (Used in) Financing Activities 1 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 7 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $40.27M 10-Q · filed 2026-08-10 | $52.93M derived: sum of 3 quarters · filed 2026-08-10 | $129.33M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $5.53M 10-Q · filed 2026-05-12 | $18.19M derived: sum of 2 quarters · filed 2026-05-12 | $94.58M derived: sum of 3 quarters · filed 2026-05-12 | $94.16M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $12.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $89.06M derived: sum of 2 quarters · filed 2026-03-12 | $88.63M derived: sum of 3 quarters · filed 2026-08-10 | $88.33M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $76.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $75.97M derived: sum of 2 quarters · filed 2026-08-10 | $75.67M 10-Q · filed 2025-11-10 | $89.62M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | -$428.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$724.00K 10-Q · filed 2026-08-10 | $13.22M derived: sum of 3 quarters · filed 2026-08-10 | $28.26M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | -$296.00K 10-Q · filed 2026-05-12 | $13.65M derived: sum of 2 quarters · filed 2026-05-12 | $28.69M derived: sum of 3 quarters · filed 2026-05-12 | $28.86M derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | $13.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $28.98M derived: sum of 2 quarters · filed 2026-03-12 | $29.15M derived: sum of 3 quarters · filed 2026-03-12 | $29.17M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $15.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $15.21M derived: sum of 2 quarters · filed 2025-11-10 | $15.22M 10-Q · filed 2025-11-10 | $4.53M derived: sum of 4 quarters · filed 2025-11-10 | |||||
| 2024-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $189.00K 10-Q · filed 2025-08-12 | -$10.51M derived: sum of 3 quarters · filed 2025-08-12 | -$10.50M derived: sum of 4 quarters · filed 2025-08-12 | |||||
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-12 | -$10.68M derived: sum of 2 quarters · filed 2025-05-12 | -$10.67M derived: sum of 3 quarters · filed 2025-05-12 | -$10.59M derived: sum of 4 quarters · filed 2025-05-12 | |||||
| 2023-12-31 | -$10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$10.69M derived: sum of 2 quarters · filed 2025-03-31 | -$10.61M derived: sum of 3 quarters · filed 2025-03-31 | $46.22M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $90.00K derived: sum of 2 quarters · filed 2024-11-12 | $56.91M 10-Q · filed 2024-11-12 | $51.82M derived: sum of 4 quarters · filed 2024-11-12 | |||||
| 2023-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $56.91M 10-Q · filed 2024-08-12 | $51.82M derived: sum of 3 quarters · filed 2024-08-12 | $49.32M derived: sum of 4 quarters · filed 2024-08-12 | |||||
| 2023-03-31 | $56.82M 10-Q · filed 2024-05-13 | $51.73M derived: sum of 2 quarters · filed 2024-05-13 | $49.23M derived: sum of 3 quarters · filed 2024-05-13 | $135.31M derived: sum of 4 quarters · filed 2024-05-13 | |||||
| 2022-12-31 | -$5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$7.59M derived: sum of 2 quarters · filed 2024-03-27 | $78.49M derived: sum of 3 quarters · filed 2024-03-27 | $103.26M 10-K · filed 2024-03-27 | -$92.59M 10-K · filed 2023-01-25 | ||||
| 2022-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $83.58M derived: sum of 2 quarters · filed 2023-11-13 | $108.35M 10-Q · filed 2023-11-13 | -$92.59M 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $86.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $110.84M 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $24.76M 10-Q · filed 2023-05-12 | ||||||||
| 2020-12-31 | $162.29M 10-K/A · filed 2022-03-31 | ||||||||
| 2020-09-30 | $162.29M 10-Q/A · filed 2022-03-31 | ||||||||
| 2020-06-30 | $193.69K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |